Our top pick for
Building a portfolio
Merus N.V is a biotechnology business based in the US. Merus N-V shares (MRUS) are listed on the NASDAQ and all prices are listed in US Dollars. Merus N-V employs 87 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$10.18 - USD$31.27|
|50-day moving average||USD$24.53|
|200-day moving average||USD$17.05|
|Wall St. target price||USD$24.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.94|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$28.7 million|
|Gross profit TTM||USD$-24,547,000|
|Return on assets TTM||-22.68%|
|Return on equity TTM||-102.92%|
|Market capitalisation||USD$881.6 million|
TTM: trailing 12 months
There are currently 687,410 Merus N-V shares held short by investors – that's known as Merus N-V's "short interest". This figure is 2.3% down from 703,526 last month.
There are a few different ways that this level of interest in shorting Merus N-V shares can be evaluated.
Merus N-V's "short interest ratio" (SIR) is the quantity of Merus N-V shares currently shorted divided by the average quantity of Merus N-V shares traded daily (recently around 249967.27272727). Merus N-V's SIR currently stands at 2.75. In other words for every 100,000 Merus N-V shares traded daily on the market, roughly 2750 shares are currently held short.
However Merus N-V's short interest can also be evaluated against the total number of Merus N-V shares, or, against the total number of tradable Merus N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Merus N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Merus N-V shares in existence, roughly 20 shares are currently held short) or 0.0224% of the tradable shares (for every 100,000 tradable Merus N-V shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Merus N-V.
Find out more about how you can short Merus N-V stock.
We're not expecting Merus N-V to pay a dividend over the next 12 months.
Over the last 12 months, Merus N-V's shares have ranged in value from as little as $10.18 up to $31.2712. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Merus N-V's is 0.6949. This would suggest that Merus N-V's shares are less volatile than average (for this exchange).
Merus N. V. , a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.